A Randomized Comparison of Reservoir-Based Polymer-Free Amphilimus-Eluting Stents Versus Everolimus-Eluting Stents With Durable Polymer in Patients With Diabetes Mellitus: The RESERVOIR Clinical Trial
Rafael Romaguera, Joan A Gómez-Hospital, Josep Gomez-Lara, Salvatore Brugaletta, Eduardo Pinar, Pilar Jiménez-Quevedo, Montserrat Gracida, Gerard Roura, Jose L Ferreiro, Luis Teruel, Eduard Montanya, Antonio Fernandez-Ortiz, Fernando Alfonso, Marco Valgimigli, Manel Sabate, Angel Cequier, Rafael Romaguera, Joan A Gómez-Hospital, Josep Gomez-Lara, Salvatore Brugaletta, Eduardo Pinar, Pilar Jiménez-Quevedo, Montserrat Gracida, Gerard Roura, Jose L Ferreiro, Luis Teruel, Eduard Montanya, Antonio Fernandez-Ortiz, Fernando Alfonso, Marco Valgimigli, Manel Sabate, Angel Cequier
Abstract
Objectives: The aim of this study was to compare the efficacy of amphilimus-eluting stents (AES) with that of everolimus-eluting stents (EES) in patients with diabetes mellitus (DM).
Background: The AES is a polymer-free drug-eluting stent that elutes sirolimus formulated with an amphiphilic carrier from laser-dug wells. This technology could be associated with a high efficacy in patients with DM.
Methods: This was a multicenter, randomized, noninferiority trial. Patients with DM medically treated with oral glucose-lowering agents or insulin and de novo coronary lesions were randomized in a 1:1 fashion to AES or EES. The primary endpoint was the neointimal (NI) volume obstruction assessed by optical coherence tomography at 9-month follow-up.
Results: A total of 116 lesions in 112 patients were randomized. Overall, 40% were insulin-treated patients, with a median HbA1c of 7.3% (interquartile range: 6.7% to 8.0%). The primary endpoint, NI volume obstruction, was 11.97 ± 5.94% for AES versus 16.11 ± 18.18% for EES, meeting the noninferiority criteria (p = 0.0003). Pre-specified subgroup analyses showed a significant interaction between stent type and glycemic control (p = 0.02), with a significant reduction in NI hyperplasia in the AES group in patients with the higher HbA1c (p = 0.03). By quantitative coronary angiography, in-stent late loss was 0.14 ± 0.24 for AES versus 0.24 ± 0.57 mm for EES (p = 0.27), with a larger minimal lumen diameter at follow-up for AES (p = 0.02), mainly driven by 2 cases of occlusive restenosis in the EES group.
Conclusions: AES are noninferior to EES for the coronary revascularization of patients with DM. These results suggest a high efficacy of the AES and may support the potential benefit of this stent in patients with DM. (A Randomized Comparison of Reservoir-Based Polymer-Free Amphilimus-Eluting Stents Versus Everolimus-Eluting Stents With Durable Polymer in Patients With Diabetes Mellitus [RESERVOIR]; NCT01710748).
Keywords: diabetes mellitus; drug-eluting stents; optical coherence tomography; restenosis.
Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Source: PubMed